Eton Pharmaceuticals, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-96.9% vs price
Base Case (Median)
-90.8% vs price
Bull Case (75th pct.)
-83.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $11.56 | -81.2% | High (40%) |
| PE Comparable | $8.46 | -86.2% | Medium (25%) |
| Graham Number | $2.88 | -95.3% | Medium (40%) |
| EV/EBITDA | $1.59 | -97.4% | Medium (20%) |
| EV/FCF | $10.95 | -82.2% | Medium (20%) |
| Earnings Power Value | $-0.13 | -100.2% | Medium (50%) |
Based on 6 out of 8 methods, ETON appears overvalued at the current price of $61.48. The base case fair value of $5.67 implies 90.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.